Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Endocrine 4NET 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 208Carcinoid Tumor 26Neoplasms 22Pancreatic Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 14Carcinoma, Neuroendocrine 11Carcinoma 11Adenoma, Islet Cell 11Neoplasm Metastasis 10Colorectal Neoplasms 9Lung Neoplasms 8Serotonin Syndrome 7Prostatic Neoplasms 7Adenocarcinoma 7Pheochromocytoma 6Gastrointestinal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Somatostatinoma 5Neuroblastoma 5Melanoma 5Gastroenteropancreatic Neuroendocrine Tumors 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Vipoma 4Sarcoma 4Rectal Neoplasms 4Paraganglioma 4

Interventions

Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Zollinger-Ellison Syndrome × NET × Clear all
NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Columbia University

Phase 2 Completed
41 enrolled 9 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡